SITEMAP
- Home
-
Science
- Cutting-Edge Science
- Inspiration and Innovation
-
Asthma
-
Cutting Edge Science
- 2021
- Innovation
-
2022
- Consider Dupixent for Asthmatic Patients with High EOS
- Consider Dupixent For asthmatic patients with OCS use
- DUPIXENT® (dupilumab) Mechanism of Action
- Discover a solution to control mixed eosinophilic and allergic asthma
- What's possible when their child's asthma is under control?
- How to inject Dupixent
-
Cutting Edge Science
- Atopic Dermatitis
-
Cardiovascular
-
Atherothrombosis
-
Cutting Edge Science
- Innovation
-
2022
- Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
- Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
- Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)
- Adherence and persistence analysis in patients treated with DAPT
- In hospital outcomes in young patients with AMI: Results from Gulf Coast
-
2023
- Clopidogrel vs Ticagrelor in ACS
- New Users of Ticagrelor / Clopidogrel Observational Study in Sweden
- Clopidogrel Based Strategies in ACS
- ESC 2021 - Dual Antiplatelet Therapy After Coronary Stenting in High Bleeding Risk Patients
- ESC 2021 - Antiplatelet therapy in high bleeding risk patients with or without OAC Therapy
- SMART-CHOICE Trial_P2Y12 Inhibitor Monotherapy in Complex PCI
- Clinical Outcome of Switching From Clopidogrel to Ticagrelor
- P2Y12 Inhibitor Adherence Trajectories in ACS
- Clopidogrel Monotherapy After Very Short DAPT
- DAPT De-Escalation Vs Standard DAPT
- Potent P2Y12 Inhibitors Vs Clopidogrel in Elderly ACS Patients
- Unguided De-Escalation from Ticagrelor to Clopidogrel
- De-escalation of DAPT for ACS
- Ticagrelor vs Clopidogrel in High Bleeding Risk Patients with ACS
- Net Clinical Benefit of Clopidogrel vs Ticagrelor
- DAPT for Secondary Prevention of AIS
- The SWITCH Study: Antiplatelet-Switching Strategy After Coronary Interventions
- P2Y12 Inhibitors After Coronary Stenting
- Clopidogrel vs Aspirin Post PCI Following DAPT
- De-Escalation to Clopidogrel in AMI
-
Cutting Edge Science
-
Dyslipidemia
-
Cutting Edge Science
-
2021
- NEJM Odyssey Outcomes
- ODYSSEY Outcomes
- Odyssey Outcomes - DM sub-analysis
- Odyssey Outcomes - Elderly Patients Results
- Odyssey Outcomes - CABG Results
- Odyssey Outcomes - PVD Results
- Odyssey Outcomes - Total Events Results
- Odyssey Outcomes - Mortality
- ESC/EAS 2019 International Guidelines
- Odyssey Outcomes - Total Events Analysis
- Effect of Alirocumab on MACE in patients with CKD
- Odyssey Outcomes - CVOT Mortality Sub-analysis
- Odyssey Outcomes - PVD Sub-analysis
- Italian real-world analysis for PCSK9 inhibitors new users
- Optimal use of LLT after ACS
- Real-life safety and efficacy of Alirocumab - ODYSSEY APPRISE study
- Regulate LDL-C level for those undergoing coronary revascularization (Diabetic Patients)
- The EXPLORER Study
- The ROSETTE Study
- The ACTE Study
- Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress
-
Innovation
- Treating to target in clinical practice: Why is it important to achieve recommended LDL-C levels?
- 2022
- Atherosclerosis: Identifying risks and improving outcomes
- Lipid Management in Patients with ACS/ASCVD
- Identifying and Treating Patients with High Lipidaemia Risk Post-ACS
- Improving Lipid Management for Patients Post-ACS
- Overview of Adherence Data with LLT Highlighting The Most Recent Data With PCSK9i
- Statin/ezetimibe SPC for better adherence to LLT
- Act Now for Your ACS Patients: Patient Identification
- Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early
- Act Now for Your ACS Patients: Optimise Your ACS Pathway
- Act Now for Your ACS Patients: Summary
- Metabolic Risk Factors and Effect of Alirocumab on CV Events
-
2022
- LDL-C in the management of high cardiovascular risk, changing the paradigm for prevention
- Importance of lipid registries in cardiovascular prevention
- PCSK9i after hospital discharge for acute MI
- Why compromise for less: Should PCSK9 inhibitors be initial therapy?
- What do US physicians and patients think about LLTs and goals of treatment?
- Should we Encourage Earlier and Broader Use of Combination Therapies in Dyslipidemia?
- PCSK9 Inhibitors in Cardiovascular Disease
- Role of Genetic Testing in Management of Dyslipidemia
- Recommendations for Residual Risk Reduction in ASCVD
- Prescription Trends of Oral Non-Statin LLTs and Their Effects on LDL-C
- Atherosclerotic Cardiovascular Disease Risk Assessment
- Relationship Between LDL-C LLTs and Risk of Stroke
- Public health Recommendations for Lp(a) Measurement
- Possible Challenges Post One Year of ESC/EAS Guidelines
- LLTs Exposure Time and Major Vascular Risk Reduction
- PCSK9i and Prevention of CVD
- LDL-C Targets in Patients with HFH
- PCSK9 Inhibitors in Real World Practice
- Event Rates and Risk Factors for Recurrent CV Events
- ESC Lpa in Clinical Practice EAS Consensus Statement
- Statin/Ezetimibe Combination VS Statin Monotherapy
- Single-Pill Combinations in Dyslipidemia
- CV Risk Management in T1DM Using Guidelines
- LDL-C The Only Causal Risk Factor for ASCVD
- Achievement of ESC/EAS LDL-C Treatment Goals After an ACS with Statin and Alirocumab
-
2021
-
Cutting Edge Science
-
Thrombosis
-
Cutting Edge Science
-
2021
- GAPS trial: Low-dose LMWH and GCS in in elective surgical inpatients at moderate or high risk VTE
- Enoxaparin monotherapy vs UFH monotherapy among inpatients with NSTEMI
- Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models
- VTE prophylaxis in surgical patients
- Incident heart failure tied to increased long-term risk for VTE
- VTE incidence after cesarean delivery
- ASH 2019 Guidelines for Surgical Prophylaxis
- Anticoagulation in COVID-19 Expert consensus from Mayo Clinic
- VTE prophylaxis in medically ill patients
- The choice of anticoagulation therapy in pregnant patients
- Unmet clinical needs in the management of VTE in at-risk patients
- Risk for VTE is higher in emergency surgery than elective procedures
- Duration of thromboprophylaxis following major abdominopelvic cancer-related surgery
- Risk factors of lower extremity DVT in patients undergone gynecological laparoscopic surgery
- Safety of preoperative LMWH in lung cancer patients
- Impact of anemia on long-term clinical outcomes in VTE
-
2022
- 2019 ESC Guidelines for Acute Pulmonary Embolism
- Risk for Post-operative Venous Thromboembolism in Patients Receiving Enoxaparin Prophylaxis
- Changing trends in VTE: Pulmonary Embolism Cases on Rise within the Last Decade
- Utility of Pregnancy-Adapted YEARS Algorithm in Diagnosis of Pulmonary Embolism
- VTE Comparison of Pregnancy-Specific Risk Scoring Systems in Hospitalized Maternity Patients
- Risk for pulmonary embolism continues beyond 6 weeks of surgery
- Trends in Pulmonary Embolism-related mortality in Europe
- Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery
- Independent Risk Factors for Venous Thromboembolism
- Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent VTE
- Benefit of Prophylaxis for Your High-Risk Surgical Patient
- Sanofi Thrombosis Summit
- Thematic Review on Perioperative Venous Thromboembolism Prophylaxis
- Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
- Global Use of RAM and Thromboprophylaxis in Hospitalized Patients
- Major GI Bleeding in VTE RIETE Analysis
- Does Early VTE Prophylaxis Prevent Mortality in Patients Hospitalized For COVID-19?
- Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
- High-Dose Thromboprophylaxis Correlated with Lower Risk of Death in Critically Ill COVID-19 Patients
- Venous Thromboembolism Risk Scores in Patients with Severe COVID-19
- Thromboprophylaxis with Enoxaparin and Lower Mortality with SARS-CoV-2 Infection
- Maternity Clot Risk Model to Predict Women at Risk of VTE
- RAM for VTE in Hospitalized Patients with Cancer and COVID-19
- Innovation
-
2021
-
Cutting Edge Science
- Cutting Edge Science
-
Atherothrombosis
-
Diabetes
-
Cutting Edge Science
-
2021
- Covid-19 & Diabetes Treatment Guideline
- The BRIGHT Study
- Reducing Risk of severe hypoglycemia: iNPHORM Study
- Unmet needs in adults with T2D receiving premixed insulin
- Effectiveness of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin
- Prevalence of Diabetes in Children and Adolescents
- Exploring the risk for severe hypoglycemia in the pool of studied patients with T1D
- Basal insulin and beyond
- Glycemic control in elderly people with T2D
- Hospitalization Rates for Acute Diabetes Complications
- Insulin treatment intensification with GLP-1RA vs basal-plusbasal-bolus regimens
- New technologies in Type 2 Diabetes management and future opportunities to improve clinical outcomes
- The Lixilan-L Study
-
Innovation
- Diabetes Your Type: Testimonial by Dr. Hussein
- Diabetes Your Type: Testimonial by Dr. Nadia
- Diabetes Your Type: Testimonial by Dr. Bassam
- T1DM Mini-Series: How to Avoid Hypoglycaemia in People with T1 Diabetes?
- T1DM Mini-Series: How Does Hypoglycaemia impact the life of people with T1 Diabetes?
- T1DM Mini-Series: Relevance of Edition JUNIOR trial results for the HCP and Patient life
- T1DM Mini-Series: Edition JUNIOR trial results
- T1DM Mini-Series: Clinical implications of having hyperglycaemia with ketosis
- T1DM Mini-Series: Severe hypoglycaemia compromises the achievement of glycaemic control
- T1DM Mini-Series: The main challenge for the kids and adolescents with T1
- SoliMix Study Results Summary Video
- T1D Treatment Practice and the SAGE Study
- Time-In-Range (TIR): How to interpret it and how it is associated with outcomes
- ADA 2021: Solimix Trial Summary
- Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
- 2022
- InRange Study
- ATTD 2021: Technology supporting initiation, titration and intensification
- ATTD 2021: Patients’ profiles for digital tools
- Summary of SAGE study on Adults with T1DM
- Do historical HbA1c values explain glycemic legacy effect of type 2 diabetes?
- Is Premixed insulin an effective treatment for type 2 diabetes uncontrolled by OADs?
- Expert consensus statement on management of older adults with type 2 diabetes (T2D)
- 2022
-
2021
-
Cutting Edge Science
- Eosinophilic Esophagitis
-
Multiple Sclerosis
-
Cutting Edge Science
-
2022
- Thalamic atrophy as a new biomarker of MS? The predictive value and how to use in clinical practice
- A promising biomarker in MS: Neurofilament light chain
- How old is your brain?
- Cognitive training – a curse or a blessing?
- The reason for MS – beyond focal inflammation
- Measuring brain atrophy. What can be done and where are we heading?
- Exercise as ”medicine” in the treatment of MS
- Cognitive decline – the invisible burden of MS?
- Falling chronically ill – How do I cope and move forward?
- The importance of Deep Grey matter in MS
- Why has our brain suddenly become of interest?
- MS Newsletter
- Innovation
-
2022
- Meet Sanofi MS Specialists
-
Cutting Edge Science
- Nasal Polyps
- Prurigo Nodularis
- Oncology and Rare Blood Disorder
-
Rare Diseases
-
Cutting Edge Science
- 2021
-
Innovation
- What are Lysosomal Storage disorders?
- What are the new diagnostics modalities used to expedite Rare Disease patients identification?
- Multidisciplinary approaches in Rare Disease Patient management in KSA
- How is LSDs prevalence & epidemiology different in our region?
- LSDs overview
- What is the role of Artificial Intelligence in accelerating patient's diagnosis?
- Multidisciplinary approaches in Rare Disease Patient management
- The role and importance of Patients Associations and Scientific societies ; Oman Experience
- The Stigma of Rare Diseases
- The role and importance of Patients Associations and Scientific societies ; UAE experience
- Social stigma
- Have you considered Pompe Disease?
- IOPD Challenges
- Extraordinary measures: what are the benefits to have such movies talking about Rare Diseases?
- Lysosomal Storage Diseases from Neurology Perspective
- When shall we think of a rare disease from Neurological perspective
- Fabry disease from cardiology perspective
- 2022
- Their Stories shaped them like Pearls
- 2022
- Meet Sanofi Specialist
- Discuss Case with an Expert
-
Cutting Edge Science
-
Vaccines
-
Influenza
-
Cutting Edge Science
- Innovation
-
2022
- Flu & People with Heart Disease
- Influenza-Focus on Diabetic Patients
- Influenza-Focus on Elderly
- Take a Stand Against Influenza: Focus on Children
- Take a Stand Against Influenza: Focus on COPD Patients
- Take a Stand Against Influenza: Focus on Cardiovascular Disease Patients
- Dr. Khadija Hafidh on the Urgency of Influenza In Diabetic Patients
- Dr. Wafaa Faysal raises urgency on influenza in pediatric population
-
Cutting Edge Science
- Meningitis
- Pertussis & Polio
-
Influenza
- Patient Support
- Products
-
Events
-
Cardiovascular
-
2021
- Dyslipidemia Webinars: Optimizing Dyslipidemia management
- VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond
- VTE Safety Zone: The Role of Thromboprophylaxis for the Prevention of VTE
- Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management
- VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis
- VTE Safety Zone: Prof. Juan Arcelus - Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery
- VTE Safety Zone: Prevention of VTE in Medically ill Patients COVID-19 and BEYOND
- What is the optimal way to assess VTE risk for high-risk medical patients?
-
2022
- Dyslipidemia Webisodes: Mortality data with Prof. Tunon
- Hypertension - The Most Important Disease in Medicine
- Hypertension - The Most Important Disease in Medicine II
- Sanofi Thrombosis Summit
- Venous Thromboembolism Burden
- Venous Thromboembolism in Acutely Medically Ill Patients
- Challenges of VTE Prophylaxis in Surgery
-
2021
-
Diabetes
- 2021
-
2022
- Nutrition and Insulin management in Ramadan
- Diabetes Guidelines in Ramadan
- Type 2 Diabetes Cost Effective Management
- What is Epilepsy
- Roadmap to antimicrobial prescribing
- Navigate new destinations in diabetes management
- Dia-Tour Inquiry Form
- Leveraging Time-In-Range to Improve The Patient Experience Video (Prof. Robert Ritzel)
- The Role of Basal Insulin in Type 2 Diabetes Webinar
- Innovation in Simplification Vs Basal Boulus
- Innovation of Iglarlexi in Intensification
- Ultimate Need for Intensification
- Rare Disease
- Vaccines
- Multiple Sclerosis
- Prurigo Nodularis
- Management of Soft Tissue and Upper Respiratory Infections
- Investigation and Treatment of Epilepsy
-
Cardiovascular
- Search
-
Sanofi in News
-
2022
- Sanofi signs multi-pronged partnership with Dasman Diabetes Institute to intensify diabetes prevention in Kuwait
- Ministry of Health organizes "KiDS" program at Expo 2020 Dubai to promote diabetes awareness at schools
- Saudi Health Council, Sanofi partner to boost diabetes studies and research in the kingdom
-
2022
- Registration